Is BASFY a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for BASF SE (BASFY) rests on Earnings recovery and raised 2026 guidance: After two years of weak chemical demand and margin pressure, BASF's second quarter of 2026 was the strongest in some time. The bear case rests on bASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. Analysts covering it publish targets from $12.00 to $16.00 against a $14.99 price, so even the professionals disagree by 29% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

BASF SE, headquartered in Ludwigshafen, Germany, is the largest chemical producer in the world by sales, with group revenue of about €59.7 billion in 2025. It makes the building blocks of modern industry: basic chemicals and petrochemicals from its integrated Verbund sites, engineering plastics and polyurethanes, battery and catalyst materials, nutrition and personal care ingredients, and crop protection products and seeds through its Agricultural Solutions division. The Verbund model, in which plants at a single site feed each other's by-products and energy, is the company's core competitive idea, and Ludwigshafen is the largest integrated chemical complex on earth. In 2025 BASF started up the main plants at a new Verbund site in Zhanjiang, China, a roughly €8.7 billion bet that the world's biggest chemical market will keep growing. The US-traded BASFY is a sponsored Level I ADR on OTCQX, with BNY Mellon as depositary and four ADRs representing one ordinary share listed on Xetra under the ticker BAS. The investment picture in October 2026 is a cyclical business in the middle of reinventing itself. Under CEO Markus Kamieth, BASF is running its "Winning Ways" strategy: separating its "core" chemicals and materials businesses from "standalone" units it plans to manage for value or sell. It closed the sale of a majority of its coatings business to Carlyle on June 30, 2026, booking a pre-tax gain of about €3.9 billion, and it is preparing a minority IPO of Agricultural Solutions targeted for 2027. Results have improved in 2026: second-quarter sales rose about 16% to roughly €17.2 billion, EBITDA before special items reached about €2.4 billion against roughly €1.6 billion a year earlier, and management raised its full-year EBITDA before special items guidance to €6.9 billion to €7.7 billion. In late September BASF confirmed exploratory talks to acquire Evonik Industries, which adds a large and still undefined variable. Shareholder returns rest on a minimum dividend of €2.25 per share through 2028 plus buyback plans, while the ongoing costs of shrinking the Ludwigshafen footprint, high European energy prices and the cycle itself are the main counterweights.

The bull case: what would have to be true for $16.00

The most optimistic published target on BASFY is $16.00, +6.7% from the $14.99 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Earnings recovery and raised 2026 guidance

After two years of weak chemical demand and margin pressure, BASF's second quarter of 2026 was the strongest in some time. Sales rose about 16% year over year to roughly €17.2 billion, with higher prices contributing about 11 percentage points and volumes about 7 points, and EBITDA before special items of about €2.4 billion beat analyst consensus of around €2.1 billion. Every segment except Surface Technologies improved, and Materials, Industrial Solutions and Agricultural Solutions came in notably above estimates. That followed a softer first quarter (sales about €16.0 billion, EBITDA before special items about €2.36 billion, hurt by more than €100 million of currency effects). Management responded by raising the 2026 range to €6.9 billion to €7.7 billion, versus €6.6 billion achieved in 2025, while keeping free cash flow guidance at €1.5 billion to €2.3 billion. Whether the price gains reflect lasting demand or temporary supply disruption is the key question for the third quarter report, scheduled for around October 28, 2026.

2. Portfolio reshaping: coatings out, agriculture toward an IPO

The Winning Ways strategy splits BASF into core businesses (Chemicals, Materials, Industrial Solutions, Nutrition & Care) and standalone businesses that can be run separately or monetised. The coatings sale to Carlyle, which closed at the end of June 2026, delivered a pre-tax disposal gain of about €3.9 billion and lifted second quarter net income to roughly €4.1 billion. Agricultural Solutions, one of the larger crop protection and seeds businesses globally, is being prepared for a minority listing targeted for 2027, with Deutsche Bank and Goldman Sachs reportedly leading preparations and BASF intending to stay the majority owner. Battery materials have also been scaled back and refocused. The intent is to show the market a simpler, more cash-focused chemical group and to surface value that analysts argue has been hidden inside the conglomerate.

3. Ludwigshafen restructuring and the China Verbund

BASF has been closing energy-intensive plants at Ludwigshafen since European gas prices spiked in 2022, and it continues to book restructuring charges there (special items were about minus €484 million in the second quarter of 2026, mainly Ludwigshafen restructuring and ERP implementation). The goal is a smaller, more competitive home site with a lower fixed cost base, backed by group-wide cost-savings programmes. At the same time the new Zhanjiang Verbund in southern China, BASF's largest single investment, started its major plants in 2025. Management expected a slightly negative earnings contribution in the first year because of start-up costs and has said it expects positive earnings from 2027. Execution on both sites, shrinking in Europe while ramping in China, shapes the medium-term margin picture.

4. Capital returns and the possible Evonik deal

BASF has committed to a dividend of at least €2.25 per share each year from 2025 through 2028, around €8 billion in total over the period, and has outlined a share buyback programme of at least €4 billion, originally pencilled in for 2027 and 2028 with a smaller buyback started earlier. Those plans were framed around 2028 targets that management has reaffirmed. The confirmed exploratory talks on Evonik Industries complicate that picture: reports indicate BASF submitted a preliminary offer for a voluntary public tender and that the RAG-Stiftung, which owns about 44% of Evonik, is central to any outcome. One Financial Times report cited a rejected offer of about €22.15 per Evonik share (about €10 billion in total), a figure not confirmed by the companies. A deal would change BASF's leverage, buyback capacity and specialty chemicals mix, so it is a live swing factor.

The bear case: what would have to be true for $12.00

The most pessimistic published target is $12.00, -19.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks BASF SE is worth if the risks below bite instead of the drivers above.

BASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. European natural gas and power costs remain structurally higher than in the US and the Middle East, which puts Ludwigshafen at a competitive disadvantage and makes further restructuring charges likely. Chinese overcapacity in many basic chemicals pressures global pricing, which affects both European margins and the returns on the Zhanjiang investment. A large acquisition such as Evonik would bring integration risk, possible antitrust remedies and higher debt, and could crowd out the buyback plans. BASF also carries litigation exposure (including PFAS-related claims in the US, where BASF Corporation settled with public water systems in 2024 but continues to defend other cases), and for US holders the euro to dollar exchange rate and German dividend withholding tax affect what the ADR actually returns.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding BASFY already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on BASFY

4 analysts cover BASFY, with an average target of $13.59 (-9.3% against $14.99) and a split of 0 buy, 2 hold, 2 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the BASFY forecast and price target page.

How is BASFY valued? (as of October 2026)

Price

$14.99

Market cap

$53.02B

P/E (TTM)

21.41

Forward P/E

22.84

Price / book

1.27

Beta

0.77

52-week range

$11.93 to $16.25

Snapshot for BASFY as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (FY 2025): ~€59.7B (~$69B)
EBITDA before special items (FY 2025): ~€6.6B
2026 EBITDA before special items guidance: €6.9B to €7.7B (raised in July)
Q2 2026 sales / EBITDA bsi: ~€17.2B / ~€2.4B
Market capitalisation: ~€47B to €48B (~$51B to $56B)
Dividend per share: €2.25 floor through 2028 (~4% yield)

BASF shares traded around €53 in early autumn 2026, which puts the ADR in the mid-teens in dollars given the four-for-one ratio. On the guided 2026 EBITDA before special items, the stock trades at a mid-single-digit EV/EBITDA multiple once net debt and pensions are added back, which is typical for European commodity-heavy chemical producers and cheaper than US specialty peers. Reported net income in 2026 is inflated by the roughly €3.9 billion coatings disposal gain, so trailing P/E figures quoted on data sites can look misleadingly low and are best read alongside the underlying EBITDA trend.

How do you decide if BASFY is a buy?

Rather than asking whether BASFY is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold BASFY indirectly through an index or sector ETF before adding more.

What would change your mind on BASFY

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Earnings recovery and raised 2026 guidance stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: bASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the BASFY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BASFY against your real portfolio and see your actual exposure before deciding.

Investing in BASF SE with AI

Connect the broker you already use and ask Walnut's AI how BASFY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does BASFY fit me?

FAQ

Is BASFY a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Earnings recovery and raised 2026 guidance, with revenue (fy 2025) at ~€59.7B (~$69B). The bear case rests on bASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. Analysts covering it are spread from $12.00 to $16.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell BASFY?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. BASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $12.00, -19.9% from the $14.99 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for BASFY?

Earnings recovery and raised 2026 guidance. After two years of weak chemical demand and margin pressure, BASF's second quarter of 2026 was the strongest in some time. The most optimistic analyst target on BASFY is $16.00, +6.7% from the $14.99 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for BASFY?

What does BASF SE do?

The world's largest chemical producer by sales, headquartered in Ludwigshafen, Germany.

What would have to change for BASFY to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Earnings recovery and raised 2026 guidance) stalling in the reported numbers rather than in the narrative, the risk above (bASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What is BASFY?

BASFY is the US ticker for BASF SE's American Depositary Receipts, which trade over the counter on the OTCQX market rather than on the NYSE or Nasdaq. BASF itself is a German company listed on the Frankfurt Stock Exchange (Xetra) under the ticker BAS, and it is a member of the DAX index. The ADR is sponsored by BASF, with BNY Mellon acting as depositary, which means the bank holds the underlying German shares and issues the receipts that trade in dollars. The ADR lets US investors hold BASF exposure in a US brokerage account without trading on a German exchange.

How does the BASFY ADR work, and what is the ratio?

Four BASFY ADRs represent one BASF ordinary share, a ratio in place since October 17, 2017, when BNY Mellon moved the programme from one-for-one to four-for-one through a 300% ADR distribution. The ADR price therefore tracks roughly one quarter of the Frankfurt share price converted from euros to dollars. Because it trades OTC, liquidity is lower and bid-ask spreads can be wider than for the home listing, and some data providers show older history that has not been adjusted for the 2017 change. BNY Mellon may also charge a small depositary service fee per ADR, typically deducted from dividends.

How does currency affect a BASFY holding?

BASF reports in euros and its home share price is set in euros, so the dollar value of BASFY moves with both the stock and the EUR/USD exchange rate. If the euro strengthens against the dollar, the ADR rises in dollar terms even if the Frankfurt price is flat, and the reverse happens when the dollar strengthens. Dividends are declared in euros and converted to dollars by the depositary before payment. BASF also has a currency exposure inside its business: in the first quarter of 2026, a weaker US dollar and Chinese renminbi cut EBITDA before special items by more than €100 million.

Walnut is informational, not investment advice, and gives no verdict on BASFY. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.